Reported Incidence of Liver Enzyme Elevations
Tigecycline, a glycylcycline antibiotic used for complicated infections, carries a risk of liver enzyme increases (primarily ALT and AST elevations). Clinical trials and post-marketing data show this occurs in 1-15% of patients, depending on dose, duration, and population. Short-term use (7-14 days) reports rates around 1-3% for significant elevations (>3x upper limit of normal, ULN). Long-term use (>14 days) lacks large randomized trials but shows higher rates, up to 10-15% in observational studies for multidrug-resistant infections.[1][2]
Long-Term Use Data and Patterns
In extended-duration studies (e.g., 28 days for ventilator-associated pneumonia), liver enzyme elevations reached 13% for ALT (>5x ULN in some cases), often reversible upon discontinuation. Real-world cohorts with tigecycline for 21+ days (e.g., abdominal infections) report 8-12% incidence, higher in patients with baseline liver issues or concurrent hepatotoxins. Elevations are typically asymptomatic and peak 1-2 weeks into therapy, resolving in 70-90% of cases without intervention.[3][4]
Risk Factors That Raise Likelihood
Likelihood increases with:
- Pre-existing liver disease (e.g., cirrhosis: 20-25% risk).
- Higher doses (100mg loading, 50mg BID).
- Concomitant drugs like valproate or statins.
- Duration >21 days, where cumulative risk may hit 15-20% based on meta-analyses.
Hepatitis or failure is rare (<1%), but monitoring is standard.[2][5]
How Does This Compare to Other Antibiotics?
Tigecycline's long-term liver risk exceeds doxycycline (2-5%) but matches or is below carbapenems like ertapenem (10-15% in prolonged use). It's higher than vancomycin (5-8%) but avoids nephrotoxicity. Guidelines recommend weekly LFTs for courses >14 days.[1][6]
Clinical Management and Reversibility
Most elevations are mild (grade 1-2) and reverse within 7-14 days of stopping. Discontinue if >8x ULN or with symptoms. No deaths directly linked in long-term data. FDA label warns of hepatic injury risk.[4][7]
Sources
[1]: FDA Tigecycline Label
[2]: DrugPatentWatch.com - Tigecycline Safety Profile
[3]: Meagher et al., Clin Infect Dis 2005 (28-day trial data)
[4]: Tasina et al., Int J Antimicrob Agents 2011 (meta-analysis)
[5]: Falagas et al., Clin Ther 2009 (risk factors review)
[6]: IDSA Guidelines, Clin Infect Dis 2016
[7]: LiverTox NIH Database - Tigecycline